Literature DB >> 16210484

Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use.

Giulia Freer1, Donatella Matteucci, Paola Mazzetti, Leonia Bozzacco, Mauro Bendinelli.   

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells that can prime T cells and polarize the cellular immune response. Because Th1-type immune responses have been connected to success in combating viral infection, a promising therapeutic application of DCs would be their differentiation in vitro and injection back into the host to boost an immune response in infected animals. This study was aimed both at developing a protocol to cultivate feline DCs in the absence of exogenous proteins for their use in vivo and at investigating what might be the most appropriate stimulus to induce their maturation in vitro and finding correlates of maturation. We generated DCs from peripheral blood monocytes in the presence of feline interleukin-4 and granulocyte-macrophage colony stimulating factor, and after 5 days their maturation was induced with either lipopolysaccharide, human recombinant tumor necrosis factor alpha, poly(I:C), or activated feline platelets. After 48 h, their CD14, CD1a, major histocompatibility complex class II, and B7.1 surface expression was analyzed in parallel with their ability to uptake antigen or prime a mixed leukocyte reaction. The results presented show that feline DCs cultured in autologous plasma differentiate and are able to mature in the presence of stimuli similar to the ones currently used for other species. The present work sets the grounds for future use of DCs obtained by the protocol described for in vivo vaccination and immunotherapy of feline immunodeficiency virus-infected cats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210484      PMCID: PMC1247835          DOI: 10.1128/CDLI.12.10.1202-1208.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  29 in total

1.  Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.

Authors:  T B Geijtenbeek; R Torensma; S J van Vliet; G C van Duijnhoven; G J Adema; Y van Kooyk; C G Figdor
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

Review 2.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infection.

Authors:  David O'Neill; Nina Bhardwaj
Journal:  Methods Mol Med       Date:  2005

3.  Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells.

Authors:  C Scheinecker; K P Machold; O Majdic; P Höcker; W Knapp; J S Smolen
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

4.  Quantitative assessment of feline epidermal Langerhans cells.

Authors:  I Saint-André Marchal; C Dezutter-Dambuyant; J P Martin; B J Willett; J C Woo; P F Moore; J P Magnol; D Schmitt; T Marchal
Journal:  Br J Dermatol       Date:  1997-06       Impact factor: 9.302

5.  Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches.

Authors:  G Müller; A Müller; H Jonuleit; K Steinbrink; C Szalma; L Paragnik; K Lingnau; E Schmidt; J Knop; A H Enk
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

6.  Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells.

Authors:  R M Verdijk; T Mutis; B Esendam; J Kamp; C J Melief; A Brand; E Goulmy
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

7.  Large-scale culture and selective maturation of human Langerhans cells from granulocyte colony-stimulating factor-mobilized CD34+ progenitors.

Authors:  E Gatti; M A Velleca; B C Biedermann; W Ma; J Unternaehrer; M W Ebersold; R Medzhitov; J S Pober; I Mellman
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

8.  Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.

Authors:  Wei Lu; Luiz Claudio Arraes; Wylla Tatiana Ferreira; Jean-Marie Andrieu
Journal:  Nat Med       Date:  2004-11-28       Impact factor: 53.440

9.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.

Authors:  F O Nestle; S Alijagic; M Gilliet; Y Sun; S Grabbe; R Dummer; G Burg; D Schadendorf
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

10.  Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

Authors:  S M Santini; C Lapenta; M Logozzi; S Parlato; M Spada; T Di Pucchio; F Belardelli
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  9 in total

1.  Feline lectin activity is critical for the cellular entry of feline infectious peritonitis virus.

Authors:  Andrew D Regan; David G Ousterout; Gary R Whittaker
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

2.  Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Francesca Tarabella; Valentina Catalucci; Enrica Ricci; Antonio Merico; Leonia Bozzacco; Mauro Pistello; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

3.  Utilization of DC-SIGN for entry of feline coronaviruses into host cells.

Authors:  Andrew D Regan; Gary R Whittaker
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

Review 4.  Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.

Authors:  Tracy L Lehman; Kevin P O'Halloran; Edward A Hoover; Paul R Avery
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

5.  In vitro assessment of the feline cell-mediated immune response against feline panleukopeniavirus, calicivirus and felid herpesvirus 1 using 5-bromo-2'-deoxyuridine labeling.

Authors:  Ben L Vermeulen; Sabine E Gleich; Annelike Dedeurwaerder; Dominique A Olyslaegers; Lowiese M Desmarets; Hannah L Dewerchin; Hans J Nauwynck
Journal:  Vet Immunol Immunopathol       Date:  2012-03-10       Impact factor: 2.046

6.  Expression of Toll-like receptors 3, 7, 9 and cytokines in feline infectious peritonitis virus-infected CRFK cells and feline peripheral monocytes.

Authors:  Megat Hamzah Megat Mazhar Khair; Gayathri Thevi Selvarajah; Abdul Rahman Omar; Farina Mustaffa-Kamal
Journal:  J Vet Sci       Date:  2022-03       Impact factor: 1.672

Review 7.  Influence of dendritic cells on viral pathogenicity.

Authors:  Giulia Freer; Donatella Matteucci
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

8.  Immunotherapy with internally inactivated virus loaded dendritic cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Francesca Tarabella; Enrica Ricci; Leonia Bozzacco; Antonio Merico; Mauro Pistello; Luca Ceccherini-Nelli; Mauro Bendinelli
Journal:  Retrovirology       Date:  2008-04-17       Impact factor: 4.602

9.  Feline hypertrophic cardiomyopathy: reduced microvascular density and involvement of CD34+ interstitial cells.

Authors:  Josep M Monné Rodríguez; Sonja Fonfara; Udo Hetzel; Anja Kipar
Journal:  Vet Pathol       Date:  2021-12-27       Impact factor: 2.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.